Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.48 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2497728 | 0.99 | GPR55 (0.51) | GPR55SMN1; SMN2MEN1KMT2ANAMPT | |
| SCHEMBL9970771 | 0.84 | MEN1 (0.48) | GPR55SMN1; SMN2MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2495643 | 0.83 | MEN1 (0.47) | GPR55SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL9967270 | 0.82 | RAB9A (0.59) | SMN1; SMN2MEN1KMT2AMAPTLMNA | |
| SCHEMBL9970761 | 0.81 | JAK2 (0.48) | SMN1; SMN2MEN1KMT2ANAMPTMAPT | |
| Hydrochloric Acid SCHEMBL2497707 | 0.80 | JAK2 (0.48) | SMN1; SMN2MEN1KMT2ANAMPTMAPT | |
| SCHEMBL9967280 | 0.79 | KMT2A (0.52) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL9970757 | 0.79 | POLB (0.51) | GPR55SMN1; SMN2MEN1KMT2ANAMPT | |
| SCHEMBL16690121 | 0.79 | MEN1 (0.67) | GPR55SMN1; SMN2MEN1KMT2ANAMPT | |
| Hydrochloric Acid SCHEMBL2492452 | 0.78 | KMT2A (0.51) | MEN1KMT2AALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| US-20120157490-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1651645-B1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | GPR55 541/4885SMN1; SMN2 1606/4885MEN1 4500/4885 |
| US-20140288118-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | GPR55 3821/4885SMN1; SMN2 139/4885MEN1 2378/4885 |
| US-20120157490-A1 | N-BIARYLAMIDES | GRIN2A, BCHE, ACHE | GPR55 1227/4885SMN1; SMN2 118/4885MEN1 3205/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | GPR55 3821/4885SMN1; SMN2 139/4885MEN1 2378/4885 |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | CHRNA7, CHRNA3, CHRNA2 | GPR55 907/4885SMN1; SMN2 2212/4885MEN1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.